This video examines an early trial studying abemaciclib for the treatment of brain metastases in patients with hormone receptor–positive, HER2-negative breast cancer.
In this video, Sara M. Tolaney, MD, MPH, of the Dana-Farber Cancer Institute in Boston, discusses an early trial studying the CDK4/6 inhibitor abemaciclib for the treatment of brain metastases in patients with hormone receptor (HR)-positive HER2-negative breast cancer.
Tolaney presented the study results (abstract 1019) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.
